Renal Resistive Index as a Predictor of Acute Renal Impairment in High-risk Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAswan University
About this trial
To study the ability of RRI, measured by bedside Doppler ultrasound, in detecting acute kidney injury in high-risk patients admitted to surgical intensive care unit, Aswan university hospital, compared with renal biomarkers and conventional assessment using urine output and serum creatinine levels.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with severe pre-eclampsia and eclampsia.
Polytraumatized patients.
Patients admitted to ICU with sepsis.
Both genders.
Disqualifiers
patients known to have CKD.
patients with congenital renal anomalies.
patients with renal transplantation.
Trial population
patients who are admitted to SICU, Aswan university hospital, after polytrauma, pre-eclampsia, eclampsia and sepsis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Early detection of acute kidney injury.
Renal artery resistive index will be measured daily.Cystatin C will be measured on admission, after 24 hours and 72 hours.
Time frame
Day 0,1,2,3,72
Diagnosis of acute kidney injury.
Renal artery resistive index will be measured daily.Cystatin C will be measured on admission, after 24 hours and 72 hours.
Time frame
Day 0,1,2,3,7Secondary outcomes
1
To grade the severity of AKI.
Using the KDIGO criteria, AKI is staged as follows: Stage 1: Increase in serum creatinine to 1.5 to 1.9 times baseline, or increase in serum creatinine by ≥0.3 mg/dL, or reduction in urine output to \<0.5 mL/kg/h for 6 to 12 h. Stage 2: Increase in serum creatinine to 2.0 to 2.9 times baseline, or reduction in urine output to \<0.5 mL/kg/h for ≥12 h. Stage 3: Increase in serum creatinine to 3.0 times baseline, or increase in serum creatinine to ≥4.0 mg/dL, or reduction in urine output to \<0.3 mL/kg/h for ≥24 h, or anuria for ≥12 h, or the initiation of renal replacement therapy, or, in patients \<18 years, decrease in estimated glomerular filtration rate (eGFR) to \<35 mL/min/1.73 m2.
Time frame
day 0,1,2,3,72
To predict clinical outcome (clinical improvement)
To predict clinical outcome (clinical improvement) at 30 days
Time frame
Day 0,1,2,3,7,303
To predict clinical outcome (necessity for renal replacement therapy)
To predict clinical outcome (necessity for renal replacement therapy) at 30 days
Time frame
Day 0,1,2,3,7,304
To predict clinical outcome (death)
To predict clinical outcome (death) at 30 days.
Time frame
Day 0,1,2,3,7,30Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov